Nasal epithelium as a proxy for bronchial epithelium for smoking-induced gene expression and expression Quantitative Trait Loci - 04/07/18
Doi : 10.1016/j.jaci.2018.01.047
Kai Imkamp, MD a, b 
, Marijn Berg a, b, c, Cornelis J. Vermeulen, PhD a, b, Irene H. Heijink, PhD b, c, Victor Guryev, PhD b, d, Huib A.M. Kerstjens, MD, PhD a, b, Gerard H. Koppelman, MD, PhD b, e, Maarten van den Berge, MD, PhD a, b, ∗, Alen Faiz, PhD a, b, c, ∗
, Marijn Berg a, b, c, Cornelis J. Vermeulen, PhD a, b, Irene H. Heijink, PhD b, c, Victor Guryev, PhD b, d, Huib A.M. Kerstjens, MD, PhD a, b, Gerard H. Koppelman, MD, PhD b, e, Maarten van den Berge, MD, PhD a, b, ∗, Alen Faiz, PhD a, b, c, ∗ a Department of Pulmonology, University Medical Center Groningen, Groningen, The Netherlands
b GRIAC (Groningen Research Institute for Asthma and COPD), Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands
c Department of Pathology & Medical Biology, Section of Medical Biology, University Medical Center Groningen, Groningen, The Netherlands
d European Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, The Netherlands
e Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands
| A.F. was funded by a Junior Investigator Longfonds grant (4.2.16.132JO) and a Stichting Astma Bestrijding grant. |
|
| Disclosure of potential conflict of interest: C. J. Vermeulen reports institutional grants pending from GlaxoSmithKline. H. A. M. Kerstjens reports institutional grants from Novartis, Boehringer Ingelheim, and GSK; speaking fees from Boehringer Ingelheim; consultant fees from AstraZeneca, Chiesi, GlaxoSmithKline, and Novartis; board membership with Chiesi, GlaxoSmithKline, and Novartis; and institutional patient fees collected during the course of the trial. G. H. Koppelman reports institutional grants from the Lung Foundation of the Netherlands, TEVA, GlaxoSmithKline, Ubbo Emmius Foundation, and TETRI Foundation. M. van den Berge reports institutional grants pending from Chiesi, GlaxoSmithKline, and TEVA. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 1
P. 314 - juillet 2018 Retour au numéro
Article précédent
- A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway
- Christopher C.T. Sng, Sorcha O'Byrne, Daniil M. Prigozhin, Matthias R. Bauer, Jennifer C. Harvey, Michelle Ruhle, Ben G. Challis, Sara Lear, Lee D. Roberts, Sarita Workman, Tobias Janowitz, Lukasz Magiera, Rainer Doffinger, Matthew S. Buckland, Duncan J. Jodrell, Robert K. Semple, Timothy J. Wilson, Yorgo Modis, James E.D. Thaventhiran
- A RAB27A 5? untranslated region structural variant associated with late-onset hemophagocytic lymphohistiocytosis and normal pigmentation
- Bianca Tesi, Jelena Rascon, Samuel C.C. Chiang, Birute Burnyte, Alexandra Löfstedt, Anders Fasth, Miriam Heizmann, Sandra Juozapaite, Rosita Kiudeliene, Egle Kvedaraite, Valdone Miseviciene, Audrone Muleviciene, Martha-Lena Müller, Magnus Nordenskjöld, Reda Matuzeviciene, Ruta Samaitiene, Carsten Speckmann, Sigita Stankeviciene, Vytautas Zekas, Matthias Voss, Stephan Ehl, Nerija Vaiciene-Magistris, Jan-Inge Henter, Marie Meeths, Yenan T. Bryceson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?